TIZETATUG REZETECAN
UNII UJR3SD8NLS

Substance Identification & Data

This profile provides standardized clinical and technical data for Tizetatug Rezetecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) UJR3SD8NLS.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2938864-88-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

UJR3SD8NLS

CAS Registry Number

2938864-88-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TIZETATUG REZETECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C211811

National Cancer Institute reference terminology for clinical and research data.

INN ID

13287

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Tizetatug Rezetecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tizetatug Rezetecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Tizetatug Rezetecan

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-451) [VH (Homo sapiens IGHV1-69*02 (88.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.14] (26-35.51-58.97-110)) (1-121) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 D12 (360), L14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-9*03 (84.3%) -IGKJ4*01 (91.7%) G120>A (100), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1SV lacking the glutamine synthetase (GS-KO) gene, glycoform alfa; substituted at the sulfur atoms of four L-cysteinyl residues on an average among 224, 230, 233, 214', 224'', 230'', 233'' and 214''' with (3RS)-1-[(2R,10S)-10-benzyl-2-cyclopropyl-1-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino}-1,6,9,12,15,18-hexaoxo-3-oxa-5,8,11,14,17-pentaazatricosan-23-yl]-2,5-dioxopyrrolidin-3-yl (rezetecan) groups

Immunoglobulin G1, anti-(human tumor-associated calcium signal transducer 2) (human-Mus musculus monoclonal HRP02606 γ1-chain), human-Mus musculus monoclonal HRP02606 κ-chain, dimer, reduced, tetrakis(thioether) with (2S)-N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[(1R)-1-cyclopropyl-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide

immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody; conjugated on an average of four cysteinyl residues to rezetecan

tizetatug rezetecan [INN]

External Clinical & Regulatory Resources

Previous UNIIUJQ9R402Z8

Next UNIIUJR6N69WMU